Literature DB >> 21574242

Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation.

Robert Schall1, Arne Ring.   

Abstract

We investigate mixed models for repeated measures data from cross-over studies in general, but in particular for data from thorough QT studies. We extend both the conventional random effects model and the saturated covariance model for univariate cross-over data to repeated measures cross-over (RMC) data; the resulting models we call the RMC model and Saturated model, respectively. Furthermore, we consider a random effects model for repeated measures cross-over data previously proposed in the literature. We assess the standard errors of point estimates and the coverage properties of confidence intervals for treatment contrasts under the various models. Our findings suggest: (i) Point estimates of treatment contrasts from all models considered are similar; (ii) Confidence intervals for treatment contrasts under the random effects model previously proposed in the literature do not have adequate coverage properties; the model therefore cannot be recommended for analysis of marginal QT prolongation; (iii) The RMC model and the Saturated model have similar precision and coverage properties; both models are suitable for assessment of marginal QT prolongation; and (iv) The Akaike Information Criterion (AIC) is not a reliable criterion for selecting a covariance model for RMC data in the following sense: the model with the smallest AIC is not necessarily associated with the highest precision for the treatment contrasts, even if the model with the smallest AIC value is also the most parsimonious model.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21574242     DOI: 10.1002/pst.463

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  5 in total

1.  The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.

Authors:  Arne Ring; Andreas Port; E Ulrike Graefe-Mody; Ivette Revollo; Mario Iovino; Klaus A Dugi
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

2.  Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods.

Authors:  Jingtao Lu; Jianguo Li; Gabriel Helmlinger; Nidal Al-Huniti
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-03-19       Impact factor: 2.745

3.  Concentration-QTc analysis with two or more correlated baselines.

Authors:  Yasushi Orihashi; Yuji Kumagai
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-05-12       Impact factor: 2.745

4.  The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.

Authors:  Arne Ring; Tobias Brand; Sreeraj Macha; Kerstin Breithaupt-Groegler; Gudrun Simons; Beate Walter; Hans J Woerle; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2013-04-24       Impact factor: 9.951

Review 5.  Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and Simulations.

Authors:  Zofia Tylutki; Sebastian Polak; Barbara Wiśniowska
Journal:  Curr Pharmacol Rep       Date:  2016-04-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.